← Back to Search

HIPEC for Bladder Cancer

N/A
Waitlist Available
Led By Douglas S Scherr, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a heated chemotherapy drug applied directly to the abdomen in patients with bladder cancer undergoing major surgery. The goal is to reduce the risk of cancer returning by making the drug more effective and targeting cancer cells directly. The treatment involves applying heated chemotherapy to the abdomen after surgical removal of tumors to kill remaining cancer cells.

Eligible Conditions
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Treatment toxicity

Side effects data

From 2024 Phase 2 trial • 51 Patients • NCT02040142
69%
Anemia
59%
Hypocalcemia
55%
Nausea
53%
Hypertension
49%
Lymphocyte Count Decreased
49%
Hyperglycemia
47%
Aspartate Aminotransferase (AST) Increased
45%
Blood Bilirubin Increased
43%
Alanine Aminotransferase (ALT) Increased
37%
White Blood Cell Decreased
29%
Hypoalbuminemia
22%
Febrile Neutropenia
8%
Fever
6%
Creatinine Increased
6%
Chronic Kidney Disease
4%
White Blood Cell Count Increased
4%
Hypophosphatemia
4%
Acute Kidney Injury
4%
Dyspnea
2%
Platelet Count Decreased
2%
Intra-abdominal Hemorrhage
2%
Abdominal Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
HIPEC + Mitomycin C

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: HIPEC after Radical CystectomyExperimental Treatment1 Intervention
After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HIPEC
2014
Completed Phase 3
~230

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,084 Previous Clinical Trials
1,147,305 Total Patients Enrolled
Douglas S Scherr, MDPrincipal InvestigatorWeill Cornell Medicine - New York Presbyterian Hospital
2 Previous Clinical Trials
28 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top